Skip to main content
SpringerLink
Log in

Antipsychotic Polypharmacy in Czech Republic and in Ukraine

  • Chapter
  • First Online:
Polypharmacy in Psychiatry Practice, Volume II

  • 1122 Accesses

Abstract

In prescription surveys, use of antipsychotic polypharmacy is common, despite scant supporting evidence. This study investigated the use of monotherapy and different types of polypharmacotherapy among inpatients with acute episodes of schizophrenia in the Czech Republic and in the Ukraine. Two hundred participants were enrolled from two sites: Lnare Psychiatric Clinic, Czech Republic (n = 100) and Psychiatric Hospital №1 in Simferopol, Crimea, Ukraine (n = 100). Each inpatient was evaluated twice with the Positive and Negative Symptom Scale (PANSS) at admission (acute stage) and at discharge (a stabilization stage) from hospital. This study revealed that antipsychotic polypharmacy was prescribed considerably more frequently in the Czech sample (43%) than in the Ukrainian group (29%). The use of combinations of first generation antipsychotics (FGAs) and second generation antipsychotics (SGAs) during hospitalization was six times more prevalent in the Czech Republic (31%) than in the Ukraine (5%; p < 0.001); 24% of the Ukranian inpatients received a combination of two or more FGAs, in comparison to 12% of the Czech inpatients (p < 0.05) at admission, and the rates decreased to 4% and 9%, respectively, at discharge (p < 0.05). Augmentation with off-label prescribed antidepressants and mood stabilizers was far more prevalent in the Ukraine (65 and 54%, at admission and discharge, respectively) than in the Czech sample (40 and 29%, at admission and discharge, respectively). Antipsychotic monotherapy for acute psychosis in the Czech Republic (20%; mainly SGAs) was almost three times more common than in the Ukraine (8%; mainly FGAs; t = 4.63, p < 0.001);. When the mental health condition stabilized, antipsychotic monotherapy was increased: from 20 to 33% in the Czech Republic and from 8 to 18% in the Ukraine. International multicenter studies are warranted to investigate the reasons for and the impact of the predominant use of polypharmacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

FGA:

First generation antipsychotics

NASMHPD:

National Association of State Mental Health Program Directors report

PANSS:

Positive and Negative Symptom Scale of Schizophrenia

SD:

Standard deviation

SGA:

Second generation antipsychotics

SSRI:

Selective serotonin reuptake inhibitor

References

  1. Sheppard C, Collins L, Fiorentino D et al (1969) Polypharmacy in psychiatric treatment. Incidence at a state hospital. Curr Therapy Res 11:765–774

    CAS  Google Scholar 

  2. Praško J, Herman E, Seiferova D (2007) Konziliární psychiatrie. Medical Tribune, Praha

    Google Scholar 

  3. Kolvach Z, Holmerova I (2010) Geriatrická farmakoterapie. In: Marek J (ed) Farmakoterapie vnitřních nemocí. Grada Publication, Praha, pp 687–695

    Google Scholar 

  4. Hovstadius B, Hovstadius K, Åstrand B et al (2010) Increasing polypharmacy – an individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol 10:16

    Article  PubMed  Google Scholar 

  5. Langan J, Shajahan P (2010) Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 34:58–62

    Article  Google Scholar 

  6. Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325–329

    Article  PubMed  CAS  Google Scholar 

  7. Boschert S (2008) Practical psychopharmacology: polypharmacy in schizophrenia is often expensive, ineffective. Elsevier Global Medical News, 12 Dec

    Google Scholar 

  8. Medical Directors Council (2001) Medical directors technical report on psychiatric polypharmacy. National Association of State Mental Health Programs Directors(NASMHPD) Alexandria, Virginia, 9 Oct

    Google Scholar 

  9. Janssen B, Weinmann S, Berger M et al (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30(4):1023–1033

    Article  PubMed  Google Scholar 

  10. Tapp A, Wood AE, Secrest L et al (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55–59

    Article  PubMed  Google Scholar 

  11. Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23(2):103–111

    Article  PubMed  Google Scholar 

  12. Kreyenbuhl J, Marcus SC, West JC et al (2007) Adding or switching antipsychotic medication in treatment-refractory schizophrenia. Psychiatr Serv 58:983–990

    Article  PubMed  Google Scholar 

  13. Buchman RW, Kreyenbuhl J, Kelly DL et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendation and summary statements. Schizophr Bull 36(1):71–93

    Article  Google Scholar 

  14. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (2010) National collaborating centre for mental health, national clinical guideline number 82. The British Psychological Society/The Royal College of Psychiatrists, London

    Google Scholar 

  15. Kapiani B (2007) The results of antipsychotic therapy of schizophrenia with connection correlated factors. Ph.D. dissertation Sankt- Petersburg

    Google Scholar 

  16. Centorrino F, Goren JL, Hennen J et al (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700–706

    Article  PubMed  Google Scholar 

  17. Tiganov AS (1999) Schizophrenia. In: Tiganov AS (ed) Textbook of psychiatry, vol II. Medicine, Moscow, pp 407–555

    Google Scholar 

  18. Maljarov SA, Demchenko VA, Vitebskaja TB (2004) What should guide the physician in appointing of combination antipsychotic therapy? Health of Ukraine 96. http://www.health-ua.org/archives/health/738.html

  19. Mosolov SN (2010) Actual theoretical problems of diagnostic, classification, neurobiology and therapy of schizophrenia: a comparison of International and Russian experience. Zh Nevrol Psikhiatr Im S S Korsakova 110(6):4–11

    PubMed  CAS  Google Scholar 

  20. Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scand 106(5):323–330

    Article  CAS  Google Scholar 

  21. Christoph U, Correll CU, Rummel-Kluge C et al (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443–457

    Article  Google Scholar 

  22. Metzer HY, Kostakoglu E (2000) Combining antipsychotics: is there evidence for efficacy? Psychiatric Times 17(9):25–34

    Google Scholar 

  23. Stahl SM (2010) Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 15(20):79–94

    PubMed  Google Scholar 

  24. Silver H (2004) Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5(10):2053–2058

    Article  PubMed  CAS  Google Scholar 

  25. Silver H, Chertkow Y, Weinreb O et al (2009) Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics 6(1):86–93

    Article  PubMed  CAS  Google Scholar 

  26. Silver H, Susser E, Danovich L et al (2011) SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol 14(5):573–584

    Article  PubMed  CAS  Google Scholar 

  27. Stahl SM (2009) Stahl’s essential psychopharmacology. Neuroscientific basis and practical application, 3rd edn. Cambridge University Press, New York

    Google Scholar 

  28. Muijen M, Silverstone T (1987) A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 150:501–504

    Article  PubMed  CAS  Google Scholar 

  29. Goren JL, Parks JJ, Chinassi FA et al (2008) When is antipsychotic polypharmacy supported by research evidence & implication for QI. Jt Comm J Qual Patient Saf 34(10):571–582

    PubMed  Google Scholar 

  30. Sadock BJ, Sadock VA, Ruiz P (eds) (2009) Kaplan and Sadock’s comprehensive textbook of psychiatry, vol II, 9th edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  31. Ghaemi SA (2002) Conceptual and historical background of polypharmacy in psychiatry. In: Ghaemi SA (ed) Polypharmacy in psychiatry. Marcel Dekker Inc, New York, pp 1–34

    Chapter  Google Scholar 

  32. Ghaemi SA (2003) Concepts of psychiatry. A plyralistic approach to mind and mental illness. The John Hopkins Press, Baltimore

    Google Scholar 

  33. Ito C, Kubota Y, Sato MA (1999) A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 53:35–40

    Article  Google Scholar 

  34. Tognoni G (1999) Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the outcome of severe mental disorders. Eur J Clin Pharmacol 55(9):685–690

    Article  PubMed  CAS  Google Scholar 

  35. Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25(5):383–399

    Article  PubMed  Google Scholar 

  36. Adeponle AB, Obembe AO, Adeyemi SO (2007) Suleiman polypharmacy in psychiatric outpatient practice in northern Nigeria. Afr J Psychiatry 10:215–218

    CAS  Google Scholar 

  37. Keks NA, Alston K, Hope J et al (1999) Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33:896–901

    Article  PubMed  CAS  Google Scholar 

  38. Cascade EF, Amir HK, Buckley PF (2008) Current management of schizophrenia: antipsychotic monotherapy versus combination therapy. Psychiatry (Edgemont) 5(5):28–30

    Google Scholar 

  39. Miller AL (2005) Polypharmacy in schizophrenia: science, art, and fiction. Curr Psychosis Ther Rep 3(2):61–67

    Article  Google Scholar 

  40. Ranceva N, Ashraf W, Odelola D (2010) Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines. J Clin Pharmacol 50(6):699–704

    Article  PubMed  CAS  Google Scholar 

  41. Dussias P, Kalali AH, Citrome L (2010) Polypharmacy of schizophrenia. Psychiatry (Edgemont) 7(8):17–19

    Google Scholar 

  42. Chiu HF, Shum PS, Lam CW (1991) Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital 37(3):187–191. http://www.ncbi.nlm.nih.gov/pubmed/1743903

  43. Sim K, Su A, Fujii S et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58(2):178–183

    Article  PubMed  Google Scholar 

  44. Pi EH, Simpson GM (2005) Psychopharmacology: cross-cultural psychopharmacology: a current clinical perspective. Psychiatric Serv 56(1)

    Google Scholar 

  45. Kreyenbuhl JA, Valenstein M, McCarthy JF et al (2007) Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatric Serv 58:489–495

    Article  Google Scholar 

  46. Verbenko NV (2007) Essays of ethnic psychiatry. In: Samokhvalov VP (ed) Simferopol, Dolja

    Google Scholar 

  47. Baandrup L, Allerup P, Nordentoft M et al (2010) Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. J Clin Psychiatry 71(11):1457–1464, Epub 2010 Oct 19

    Article  PubMed  Google Scholar 

  48. Stahl SM (1999) Antipsychotic polypharmacy. Part 1: therapeutic option or dirty little secret? J Clin Psychiatry 60(7):425–426

    Article  PubMed  CAS  Google Scholar 

  49. Miller AL, Craig CS (2002) Combination antipsychotics: pros, cons, and questions. Schizophr Bull 28(1):105–109

    Article  PubMed  Google Scholar 

  50. Taylor D (2010) Antipsychotic polypharmacy – confusion reigns. Psychiatrist 34:41–43

    Article  Google Scholar 

  51. Rebala K, Mikulich A, Tsybovsky J et al (2007) Y-STR variation among Slavs: evidence for the Slavic homeland in the middle Dnieper basin. J Hum Genet 52(5):406–414

    Article  PubMed  Google Scholar 

  52. Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One 3(9):e3150

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors express their gratitude to Dr. Vladimir Muchl, the director of the psychiatric hospital in Lnare (Czech Republic), and Dr. Irina A. Strojevskaja, chief of the acute department of Crimean Psychiatric Hospital № 1(Simferopol, Crimea, Ukraine).

Authors wish to express gratitude to Ms. Rena Kurs, B.A. (Shaar-Menashe Mental Health Center, Hadera, Israel) for editorial assistance.

Author information

Authors and Affiliations

  1. Deutsch-Russische Gesellschaft für Psychiatrie, Psychotherapie und Psychosoziale Gesundheit, Nürnberg, Germany

    Viktor P. Samokhvalov M.D., Ph.D., D.Sc.

  2. Department of Psychiatry, Central Military Hospital – Military University Hospital, Prague, Czech Republic

    Oksana E. Samokhvalova M.D., Ph.D.

  3. Department of Psychiatry, Crimean Medical University, Simferopol, Crimea, Ukraine

    Viktoria A. Verbenko M.D., Ph.D. & Georgij N. Verbenko M.D.

Authors
  1. Viktor P. Samokhvalov M.D., Ph.D., D.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oksana E. Samokhvalova M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Viktoria A. Verbenko M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georgij N. Verbenko M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Viktor P. Samokhvalov M.D., Ph.D., D.Sc. .

Editor information

Editors and Affiliations

  1. Sha'ar Menashe Mental Health Center, Hadera, 38814, Israel

    Michael S. Ritsner

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Samokhvalov, V.P., Samokhvalova, O.E., Verbenko, V.A., Verbenko, G.N. (2013). Antipsychotic Polypharmacy in Czech Republic and in Ukraine. In: Ritsner, M. (eds) Polypharmacy in Psychiatry Practice, Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5799-8_3

Download citation

Publish with us

Policies and ethics

Search

Navigation